Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer

Table 3 Clinical trials of pidermal growth factor receptor tyrosine kinase inhibitors in the management of unresectable pidermal growth factor receptor-mutated non-small-cell lung cancer

Clinical trial	Type of study	Sample size	Primary outcome	Stage	Treatment	TKI duration	RR	PFS	OS
RECEL, Xing et al[70]	Phase II	40	PFS	III unresectable	Erlotinib + RT vs cisplatin-etoposide + RT	2 yr	70% vs 61.9%; P = 0.744	24.5 vs 9 mo; HR: 0.104; P < 0.001	Not reported
Lee et al[71]	Phase II	59 (12 with EGFR mutation)	RR, toxicity and OS	III unresectable	EGFR mutation: erlotinib x 3 → erlotinib+RT → erlotinib x 6 vs erlotinib x 3 → cisplatin-irinotecan+RTNative/unknown EGFR: cisplatin-irinotecan × 3 → cisplatin-irinotecan+RT vs cisplatin-irinotecan+RT → cisplatin-irinotecan x 3	33 wk	EGFR mutation: 71.4% vs 80%Native/unknown EGFR: 70% vs 73.9%	EGFR mutation: 11.6 vs 8.1 moNative/unknown EGFR: 9 vs 12.3 mo	EGFR mutation: 39.3 vs 31.2 moNative/unknownEGFR: 16.3 vs 25.3 moMutated vs native EGFR: 74.8 vs 25.3 mo, P = 0.034
LOGIK0902/OLCSG0905, Saeki et al[73]	Phase II	20	2-yr OS	III unresectable	Gefitinib cisplatin-docetaxel+RT	8 wk	85%	2-yr PFS 36.9%	2-yr OS 90%

HR: Hazard ratio; OS: Overall survival; PFS: Progression-free survival; RR: Response rate; RT: Radiotherapy; TKI: Tyrosine kinase inhibitors.